Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Populus nigra pollen is an allergenic extract derived from the pollen of the black poplar (also known as Lombardy poplar). It is used primarily as a diagnostic tool for skin testing to identify immediate hypersensitivity (Type I) allergies and as a therapeutic agent in allergen immunotherapy (desensitization). By exposing the patient's immune system to controlled, increasing doses of the allergen, it aims to induce immunological tolerance and reduce symptoms associated with allergic rhinitis, allergic conjunctivitis, or asthma triggered by poplar pollen. It was first approved by the FDA in 1965 and is produced as a non-standardized solution for intradermal, percutaneous, or subcutaneous administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on populus nigra pollen.